<DOC>
	<DOCNO>NCT01424709</DOCNO>
	<brief_summary>Gemcitabine , docetaxel , CPT-11 cisplatin effective 1st line treatment advance non-small cell lung cancer ( NSCLC ) . Platinum-based doublet include gemcitabine , docetaxel CPT-11 standard 1st regimen . BRCA1 RRM1 expression level report associated sensitivity tumor cell cytotoxic agent . Some Phase II III trial prove feasibility customize chemotherapy base upon expression level one two biomarkers NSCLC patient . The investigator think customize chemotherapy may improve efficacy chemotherapy advance NSCLC . But randomise trial compare efficacy standard chemotherapy individualize chemotherapy set . So , investigator plan initiate phase II trial compare efficacy standard chemotherapy gemcitabine/cisplatin versus customized chemotherapy chemonaive NSCLC patient .</brief_summary>
	<brief_title>Individualized Chemotherapy Based BRCA1 RRM1 mRNA Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Primary end point : ORR Secondary end point : PFS , OS , safety , QOL , etc .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Written informed consent , 2 . Histologically confirm stage M1a M1b NSCLC , 3 . Aged 18 year old , 4 . Measurable disease , 5 . Life expectancy least 12 week , 6 . No prior chemotherapy target therapy , 7 . No brain metastases spinal cord compression , 8 . Less 10 % body weight loss , 9 . ECOG performance status 02 , 10 . Adequate vital organ function ( haematological , renal , hepatic , etc ) . 11 . Enough tissue detection BRCA1 RRM1 expression . 1 . Prior systemic cytotoxic chemotherapy EGFR TKI therapy , 2 . Positive pregnancy test , 3 . Another active malignancy , superficial basal cell squamous cell carcinoma situ cervix , within last 5 year , 4 . Patients brain metastasis spinal cord compression , 5 . Allergy gemcitabine , cisplatin , docetaxel , CPT11 , 6 . Any unstable systemic disease include active infection , 7 . No enough tissue detection BRCA1 RRM1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Individual therapy</keyword>
	<keyword>RRM1</keyword>
	<keyword>BRCA1</keyword>
</DOC>